Antitumor activity of Titanocene Y in xenografted PC3 tumors in mice
Dowling, C.M. , Claffrey, J., Cuffe, S., Fichtner, I., Pampillon, C., Sweeney, N.J., Strohfeldt, K., Watson, R., William, G. and Tacke, M. (2008) Antitumor activity of Titanocene Y in xenografted PC3 tumors in mice. Letters in Drug Design & Discovery, 5 (2). pp. 141-144. ISSN 1570-1808
Full text not archived in this repository.
To link to this article DOI: 10.2174/157018008783928463
Chemotherapeutic options for androgen-independent prostate cancer are extremely limited with minimum survival advantage. The benzyl-substituted unbridged titanocene bis-[(p-methoxybenzyl) cyclopentadienyl] titanium(IV) dichloride (Titanocene Y) was tested in vitro against the human prostate cancer androgen-independent cell, PC-3, which demonstrated an IC50 value of 56 x 10(-6) mol/L compared to 5.6 x 10(-6) mol/L for cisplatin. Then Titanocene Y was given at the maximum tolerable dose of 40 mg/kg/d on five consecutive days to one cohort of eight PC3 tumor-bearing male NMRI: nu/nu mice, while a second cohort was treated similarly with 3 mg/kg/d of cisplatin. Both of these mouse cohorts showed a statistically significant tumor growth reduction with respect to the third solvent-treated control group, which led to T/C values of 42% for cisplatin and 52% for Titanocene Y at the end of the experiment. This encouraging activity of Titanocene Y against prostate tumors in vivo, which is almost comparable with respect to cisplatin hopefully leads to further development of Titanocene Y in the future.